Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances

Ocugen is targeting three BLA filings: OCU400 for retinitis pigmentosa after top-line data expected in Q1 2027, OCU410ST for Stargardt disease after data anticipated in Q2 2027, and OCU410 for geographic atrophy in late 2028.

The OCU410ST Stargardt study will continue after an independent monitoring review found the treatment effect was expected to be neutral in the partial data examined; the company is awaiting full 12-month results.

Ocugen has begun the Phase III ArMaDa3 trial for OCU410, expects data in the second half of 2028, and is planning to extend its cash runway into 2028 through partnerships, non-dilutive funding and other financing options.

Ocugen NASDAQ: OCGN is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri said during a company discussion.

The company expects top-line data from its OCU400 retinitis pigmentosa program in the first quarter of 2027, followed by a rolling BLA submission. Top-line data from OCU410ST in Stargardt disease is projected for the second quarter of 2027, while Ocugen is targeting a late-2028 BLA submission for OCU410 in geographic atrophy.

Musunuri said Ocugen’s modifier gene therapy platform is designed to target master regulatory genes rather than individual disease-causing mutations. Retinitis pigmentosa can be caused by mutations in more than 100 genes, he said, while Stargardt disease involves substantial genetic and patient-population heterogeneity.

“Our therapies are potentially one-time treatments for life,” Musunuri said, describing the approach as potentially applicable across broad patient populations rather than small groups defined by a single mutation.

For OCU400, Musunuri said the company has completed process performance qualification runs and process validation activities. It also introduced two commercial-scale lots into its Phase III program. The nonclinical and chemistry, manufacturing and controls modules are ready, he said, leaving clinical data as the primary remaining component for a filing.

Following OCU400 data, Ocugen plans to meet with the U.S. Food and Drug Administration in a pre-BLA meeting and align on its submission plan. Musunuri also said the European Medicines Agency waived additional clinical-trial requirements for OCU400 and OCU410ST, allowing Ocugen to use its U.S. clinical data in European marketing authorization filings.

Musunuri addressed a Sept. 3 update on a pre-specified independent data monitoring committee review of 26 OCU410ST-treated subjects. He said the review was blinded and found that lesion-size differences did not favor the treatment group in the partial data reviewed. According to Musunuri, the committee’s assessment of the full data set indicated the effect was expected to be neutral, and its ultimate recommendation was to continue the study.

He attributed some uncertainty to the small data set and variability in lesion size among participants. “The bottom line is the study is continuing,” Musunuri said, adding that investors should wait for top-line data from the 12-month study. He said the company has added resources to the program, including a retinal specialist serving as chief medical officer.

Ocugen expects the pivotal Phase II/III GARDian3 study of OCU410ST to produce top-line results in the second quarter of 2027, according to the operator’s introduction.

Ocugen dosed the first patient in...